Affimed N.V. (NASDAQ:AFMD) Q4 2022 Earnings Call Transcript

And once we have seen this data, we will have a further decision how to proceed also in peripheral T-cell lymphoma. Based on the limited data that we have seen in these 4 patients at MD Anderson, we believe that also peripheral T-cell lymphoma is an indication that will benefit from the combination of NK cells and AFM13.

Operator: I’m showing no additional questions at this time. I’ll turn back to the speakers if there’s any closing remarks.

Adi Hoess: Yes. Thank you very much for listening in. This finishes our year-end update call of the year 2022. And as we’ve just mentioned, we have a lot of milestones coming up, in particular, for AFM13 with the initiation of the registration-directed study based on a filing and feedback from FDA. hopefully to come soon. And then we have 24 with multiple data readouts starting in Q2 but basically going into Q3 and Q4 of this year. And last but not least, the AFM28 is open for recruitment. So again, that should lead to hopefully some initial data but we’ll keep you updated as usual, at least on the earnings calls. And we will also move forward when we have some reasonable data to submit further abstract. With that, I conclude the call and thank you for listening in.

Operator: Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation. You may now disconnect.